Study of Diosmin and Hesperidin Combination to Protect Against Kidney Damage from Platinum Chemotherapy in Cancer Patients

What this Trial Is About

Researchers are evaluating the protective effects of a combination of diosmin and hesperidin on kidney damage caused by platinum-based chemotherapy in cancer patients. This prospective randomized controlled study aims to understand whether this combination can reduce nephrotoxicity associated with platinum compounds used in cancer treatment. The study involves about 100 cancer patients between 18 and 75 years old who are receiving platinum compound chemotherapy. Participants are divided into two groups one group receives standard platinum compound chemotherapy alone, while the other group receives the same chemotherapy plus an oral dose of 450 mg diosmin and 50 mg hesperidin twice daily. The study is conducted from February 2025 to September 2025, with follow-up continuing for 6 months after treatment to assess kidney function. During the study, researchers will measure serum creatinine and blood urea levels six months after treatment to evaluate kidney health. They will also monitor hemoglobin levels as a secondary outcome. Participants will be closely observed for any side effects and adherence to the treatment protocol. The study is sponsored by Beni-Suef University and aims to provide insights into managing chemotherapy-induced kidney damage in cancer patients.

Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients